Stock is my life
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My two performers SRPX and VPRO
SRPX Bought at 1.25
Short term Target $4 (Market Cap of $1Mil only At $4)
VPRO Bought at 0.045/0.05 - Target .20 (Like Jan 2011)
Whats Market Cap now ? I think that even at $4 it is only about $1M
I like to get in ground floor like I did it in SRPX 1.25 and VPRO 0.45
They should mention the SPPI partnership from Jan 2011 that made them go up from 2 cents to 20 cents
That way we do not need to advertise so much !
It already up 100% since July - SRPX is slow progress I like that
Even at $4 it is at $1M market Cap
Yes SRPX is on fire of late 7 days
Pure Hope of 1/10 of SPPI with 570M market Cap now
Wish I had SAPX instead of SRPX though - $150K in morning a house in Iowa turns to $500K by evening with house in Prinecton !lol
SRPX is on fire for last 7 days (1 1/2 weeks of trading) - All 7 days Closing higher then before !
Disclosure
I have SRPX and VPRO
If VPRO reaches 1/10th of SPPI we are looking 57M Market cap at 0.30 or so !
Price Action for last 5 years
Highest Value
2006 1.42 (approx 5/1/2006)
2007 0.37 (4/1/)
2008 0.084
2009 and 2010 - High of around only around 0.025
2011 0.20 high so far!
On the rise again !
1.
http://seekingalpha.com/article/281283-don-t-miss-out-on-upcoming-boom-in-biosimilars?source=email_portfolio
2.
http://www.pharmatimes.com/Article/11-01-06/Spectrum_plans_to_develop_biosimilar_Rituxan.aspx
If VPRO reaches 1/10th of SPPI we are looking 57M Market cap at 0.30 or so !
Price Action for last 5 years
Highest Value
2006 1.42 (approx 5/1/2006)
2007 0.37 (4/1/)
2008 0.084
2009 and 2010 - High of around only around 0.025
2011 0.20 high so far!
On the rise again !
Lotf of guys posting comments on missing out VPRO while mentioning SPPI since they both are in tie up for the Bio
SPPI is around 570M while VPRO 10M - Hope VPRO can be 1/10th of SPPI soon ! Thats 0.30 for VPRO !
SeekAlpha latest Article on SPPI/VPRO
http://seekingalpha.com/article/281283-don-t-miss-out-on-upcoming-boom-in-biosimilars?source=email_portfolio
SRPX Price Action and Resistance Watch
http://www.barchart.com/cheatsheet.php?sym=SRPX
Pivot Point 2nd Level Resistance
2.1333
Pivot Point 1st Level Resistance
2.0667
4 Week High
13 Week High
52 Week High
2.0500
Current Price
2.0000
And signal All Buys
VPRO Huge potential with July 28th data coming up for News
Older article during ascent of VPRO to 0.20 in Jan 2011
VPRO Some nice article from past during VPRO 0.20 :
http://www.pharmatimes.com/Article/11-01-06/Spectrum_plans_to_develop_biosimilar_Rituxan.aspx
Spectrum plans to develop biosimilar Rituxan
WORLD NEWS | JANUARY 06, 2011
US drugmaker Spectrum Pharmaceuticals has said it plans to develop a biosimilar version of Roche and Biogen Idec's cancer and arthritis drug Mabthera/Rituxan (rituximab), with the help of Canadian partner Viropro.
While specific financial aspects of the agreement have not been revealed, Viropro said it is a "multimillion" dollar contract and that it stands to receive milestone payments over a period of three years, as well as royalties on eventual sales.
Related Links
EMA publishes biosimilar friendly guidelines
“Consistent global approach” to biosimilars urged
Teva and Lonza JV will target potentially lucrative biosimilar market
Rituxan is Roche's second biggest-selling product with sales of almost $6 billion a year in indications including non-Hodgkin's lymphoma, chronic lymphocytic lymphoma and rheumatoid arthritis. In the past Roche has claimed patent protection for the drug until at least 2015 and possibly 2018 in the USA and 2013 elsewhere, and Spectrum has indicated only that it plans to enter the market on "patent expirations for rituximab over the coming years."
The US cancer specialist has no heritage in biosimilars. Its two commercialised products were bought-in from other companies, and it has a pipeline of novel oncology drugs both developed in-house and in-licensed. It can however offer specialist sales and marketing network in oncology, while Viropro brings its expertise in cell culture and bioprocessing technologies to the alliance.
Indeed, Viropro has made no secret of its desire to find commercial partners for its biosimilar cell lines and manufacturing processes, and its president and chief executive Dr. Rajiv Datar said the Spectrum alliance was "an important breakthrough for us in the North American market."
The announcement comes a few months after Israeli generics giant Teva Pharmaceutical Industries said it had started clinical testing of its own biosimilar version of rituximab.
Teva is expected to put in a strong bid in the emerging biosimilar market given its two-year-old alliance with contract manufacturer Lonza. That said, Spectrum would likely have to capture only a small percentage of Rituxan's market share in order to recoup a healthy return on its investment.
With over $30 billion-worth of biologic drugs losing patent protection within the coming years, analysts have estimated that biosimilars could quickly become a $10 billion category.
A number of biosimilar products are already in the market in Europe, notes Spectrum, and since the enactment of the Biologics Price Competition and Innovation Act of 2009 an abbreviated approval pathway for biosimilars has been created in the USA.
VPRO Some nice article from past during VPRO 0.20 :
http://www.pharmatimes.com/Article/11-01-06/Spectrum_plans_to_develop_biosimilar_Rituxan.aspx
Spectrum plans to develop biosimilar Rituxan
WORLD NEWS | JANUARY 06, 2011
US drugmaker Spectrum Pharmaceuticals has said it plans to develop a biosimilar version of Roche and Biogen Idec's cancer and arthritis drug Mabthera/Rituxan (rituximab), with the help of Canadian partner Viropro.
While specific financial aspects of the agreement have not been revealed, Viropro said it is a "multimillion" dollar contract and that it stands to receive milestone payments over a period of three years, as well as royalties on eventual sales.
Related Links
EMA publishes biosimilar friendly guidelines
“Consistent global approach” to biosimilars urged
Teva and Lonza JV will target potentially lucrative biosimilar market
Rituxan is Roche's second biggest-selling product with sales of almost $6 billion a year in indications including non-Hodgkin's lymphoma, chronic lymphocytic lymphoma and rheumatoid arthritis. In the past Roche has claimed patent protection for the drug until at least 2015 and possibly 2018 in the USA and 2013 elsewhere, and Spectrum has indicated only that it plans to enter the market on "patent expirations for rituximab over the coming years."
The US cancer specialist has no heritage in biosimilars. Its two commercialised products were bought-in from other companies, and it has a pipeline of novel oncology drugs both developed in-house and in-licensed. It can however offer specialist sales and marketing network in oncology, while Viropro brings its expertise in cell culture and bioprocessing technologies to the alliance.
Indeed, Viropro has made no secret of its desire to find commercial partners for its biosimilar cell lines and manufacturing processes, and its president and chief executive Dr. Rajiv Datar said the Spectrum alliance was "an important breakthrough for us in the North American market."
The announcement comes a few months after Israeli generics giant Teva Pharmaceutical Industries said it had started clinical testing of its own biosimilar version of rituximab.
Teva is expected to put in a strong bid in the emerging biosimilar market given its two-year-old alliance with contract manufacturer Lonza. That said, Spectrum would likely have to capture only a small percentage of Rituxan's market share in order to recoup a healthy return on its investment.
With over $30 billion-worth of biologic drugs losing patent protection within the coming years, analysts have estimated that biosimilars could quickly become a $10 billion category.
A number of biosimilar products are already in the market in Europe, notes Spectrum, and since the enactment of the Biologics Price Competition and Innovation Act of 2009 an abbreviated approval pathway for biosimilars has been created in the USA.
Now for the last 7 days - Looks good
Date Open High Low Close Volume
Jul 25, 2011 1.95 2.05 1.90 2.00 48,965
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
See SRPX action last 7 days :
Date Open High Low Close Volume
Jul 25, 2011 1.95 2.05 1.90 2.00 48,965
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
Closing Higher each day
Hope it does as good as SAPX
No issues with 0.20 !lol
With SAPX action today - SRPX action got dwarfed - Just difference of one letter !
It rose to high of .20 during the Spectrum news in early Jan
It can easily reach .10 now
VPRO Nice stock to own with SPPI partnership for a pinkie
SPPI ran from 8s to 11s recently
Pivot Point 2nd Level Resistance
0.0646
Pivot Point 1st Level Resistance
0.0613
4 Week High
0.0600
0.0579
Current Price
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Pivot Point 2nd Level Resistance
0.0646
Pivot Point 1st Level Resistance
0.0613
4 Week High
0.0600
0.0579
Current Price
CEO background impressive
Dr Rajiv Datar, President and Chief Executive Officer
Dr Datar holds a Ph. D in Bioprocess Technology from the Royal Institute of Technology of Stockholm, Sweden and Post-Doctorate in Biochemical Engineering from the Massasuchetts Institute of Technology (MIT). He has graduated as Biochemist / Chemist from the University of Pune, India and has Post-Graduate studies in Chemical Engineering from the University of Manchester, United Kingdom.
With 22 years experience in Biotechnology and Bio-Business in Senior Technical positions at major pharmaceutical concerns as well as Senior Management positions for publicly-traded or startup biotech, Dr Datar brings an impressive and extensive expertise to the Company.
Moreover, Dr Datar has hands-on knowledge and experience of successful conclusion of business deals, collaborations (across institutions, companies and countries), public issues, in-licensing and out-licensing deals, raising capital, positioning and sale of technologies/departments, takeovers and biotech start-ups. Dr Datar is also member of several Advisory / Boar
The cols are displaced - Leftmost figure is Opening price , then high then low then close
SAPX, SRPX all doing well Of course SAPX is on tear !
VPRO /SPPI old article
7/7 article : Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
Look at SRPX last 6 days action - Impressive
Date Open High Low Close Volume
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
SPPI will rise in future just like it did
VPRO might benefit too
7/7 article : Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
One of my friends switched industry from Biotech to Waste Management in Texas (Consulting using Siperian)
Before leaving - He would point to garbage and say
"I love Trash"
Their partnership with SPPI will give them gains
SPPI is on tear last week from 9 to almost 12
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
SRPX 2.05 On fire for last 6 days from 1.50 level
Look at Barchart ;
http://www.barchart.com/opinions/stocks/SRPX
All BUYS
and Trader's cheat sheet 2nd level resistance at 2.067
Then off to $3
SRPX has been moving up for last 7 days This being 7th day - not just today
Proof :
Date Open High Low Close Volume
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
Awesome Last 6 days action and now 7th day 2.02
Date Open High Low Close Volume
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
SRPX I have been touting it since 1.60 Now people are noticing -
Well It rose to $15 last May
At $4 it co is worth $1M SO lots more to go
SRPX 2.02 ask
From Google Finance History for last 60-7 days
Date Open High Low Close Volume
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837
SRPX 2.02 ask
From Google Finance History for last 60-7 days
Date Open High Low Close Volume
Jul 22, 2011 1.93 1.93 1.86 1.93 11,730
Jul 21, 2011 1.77 1.93 1.77 1.87 28,530
Jul 20, 2011 1.76 1.77 1.50 1.77 29,480
Jul 19, 2011 1.71 1.75 1.65 1.75 73,190
Jul 18, 2011 1.57 1.71 1.57 1.68 46,948
Jul 15, 2011 1.54 1.55 1.53 1.55 1,837